• Latest Posts

Celyad’s unique CAR-T approach is ready for Efficacy Studies

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

ADVERTISEMENT

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Nanobody Phase II Results for Arthritis: Good but not good enough?

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

June was a Tough Month for European Biotech… #Fail

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

ADVERTISEMENT